DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing Crohn's Disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Perianal Fistula Due to Crohn's Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Direct Biologics, LLC
- Last updated on ClinicalTrials.gov
- May 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Colorado · 1
- Direct Biologics Investigational Site · Aurora, CO
Missouri · 1
- Direct Biologics Investigational Site · St Louis, MO
New York · 1
- Columbia University Irving Medical Center/NYPH · New York, NY
Pennsylvania · 1
- Direct Biologics Investigational Site · Philadelphia, PA
Tennessee · 1
- Direct Biologics Investigational Site · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.